bluebird bio Past Earnings Performance
Past criteria checks 0/6
bluebird bio has been growing earnings at an average annual rate of 18.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 30.2% per year.
Key information
18.9%
Earnings growth rate
26.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -30.2% |
| Return on equity | -41.0% |
| Net Margin | -419.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
bluebird bio Is Priced Below IP Value
Mar 23Bluebird Bio: Innovative Therapies, Monetary Setbacks
Jan 25Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Oct 04Bluebird bio names interim finance chief
Sep 26Bluebird bio jumps 17% on FDA approval of new gene therapy
Sep 19bluebird bio' chief strategy and financial officer to depart
Sep 12FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia
Aug 17bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case
Jun 22bluebird bio: Beaten Down Biotech With Possible Long-Term Potential
May 09Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval
Feb 07bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success
Dec 12bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely
Nov 08bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea
Nov 03Revenue & Expenses BreakdownBeta
How bluebird bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 22 | -91 | 149 | -52 |
| 30 Jun 23 | 9 | -96 | 139 | -50 |
| 31 Mar 23 | 4 | -123 | 137 | -31 |
| 31 Dec 22 | 4 | -267 | 137 | 0 |
| 30 Sep 22 | 5 | -431 | 159 | 178 |
| 30 Jun 22 | 6 | -507 | 180 | 125 |
| 31 Mar 22 | 5 | -563 | 190 | 70 |
| 31 Dec 21 | 4 | -563 | 210 | 0 |
| 30 Sep 21 | -238 | -573 | 187 | 0 |
| 30 Jun 21 | -220 | -614 | 217 | 0 |
| 31 Mar 21 | -21 | -480 | 230 | 0 |
| 31 Dec 20 | 0 | -561 | 240 | 0 |
| 30 Sep 20 | 250 | -642 | 286 | 0 |
| 30 Jun 20 | 240 | -653 | 284 | 0 |
| 31 Mar 20 | 54 | -828 | 284 | 0 |
| 31 Dec 19 | 0 | -555 | 236 | 0 |
| 30 Sep 19 | 54 | -715 | 249 | 0 |
| 30 Jun 19 | 57 | -655 | 227 | 0 |
| 31 Mar 19 | 51 | -605 | 199 | 0 |
| 31 Dec 18 | 55 | -556 | 174 | 0 |
| 30 Sep 18 | 40 | -524 | 150 | 0 |
| 30 Jun 18 | 36 | -457 | 128 | 0 |
| 31 Mar 18 | 45 | -382 | 108 | 0 |
| 31 Dec 17 | 35 | -336 | 94 | 0 |
| 30 Sep 17 | 33 | -290 | 81 | 0 |
| 30 Jun 17 | 27 | -288 | 72 | 0 |
| 31 Mar 17 | 11 | -276 | 69 | 0 |
| 31 Dec 16 | 6 | -264 | 65 | 0 |
| 30 Sep 16 | 6 | -239 | 63 | 0 |
| 30 Jun 16 | 6 | -205 | 62 | 0 |
| 31 Mar 16 | 9 | -198 | 55 | 0 |
| 31 Dec 15 | 14 | -167 | 46 | 0 |
| 30 Sep 15 | 19 | -139 | 36 | 0 |
| 30 Jun 15 | 24 | -113 | 29 | 0 |
| 31 Mar 15 | 25 | -63 | 24 | 0 |
| 31 Dec 14 | 25 | -49 | 23 | 0 |
| 30 Sep 14 | 25 | -37 | 23 | 0 |
| 30 Jun 14 | 25 | -26 | 20 | 0 |
| 31 Mar 14 | 25 | -29 | 17 | 0 |
| 31 Dec 13 | 20 | -25 | 14 | 0 |
| 30 Sep 13 | 14 | -21 | 12 | 0 |
| 30 Jun 13 | 8 | -15 | 10 | 0 |
Quality Earnings: BLUE is currently unprofitable.
Growing Profit Margin: BLUE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLUE is unprofitable, but has reduced losses over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare BLUE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: BLUE has a negative Return on Equity (-40.97%), as it is currently unprofitable.